TSE:ONC - Oncolytics Biotech Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started C$4.11 -0.11 (-2.61 %) (As of 10/16/2018 09:59 AM ET)Previous CloseC$4.22Today's RangeC$4.07 - C$4.2152-Week RangeC$4.10 - C$10.65Volume7,808 shsAverage Volume29,918 shsMarket CapitalizationC$111.15 millionP/E RatioN/ADividend YieldN/ABeta1.04 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryInsider TradesHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada. Receive ONC News and Ratings via Email Sign-up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange TSE Industry Biotechnology Sub-IndustryN/A SectorMedical SymbolTSE:ONC CUSIPN/A Webwww.oncolyticsbiotech.com Phone+1-403-6707380 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on Equity-91.52% Return on Assets-74.32% Miscellaneous EmployeesN/A Outstanding Shares16,532,000Market CapC$111.15 million Oncolytics Biotech (TSE:ONC) Frequently Asked Questions What is Oncolytics Biotech's stock symbol? Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC." How were Oncolytics Biotech's earnings last quarter? Oncolytics Biotech, Inc. (TSE:ONC) released its quarterly earnings data on Friday, August, 3rd. The company reported ($0.27) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.01. View Oncolytics Biotech's Earnings History. When is Oncolytics Biotech's next earnings date? Oncolytics Biotech is scheduled to release their next quarterly earnings announcement on Wednesday, November 14th 2018. View Earnings Estimates for Oncolytics Biotech. What price target have analysts set for ONC? 2 equities research analysts have issued twelve-month price targets for Oncolytics Biotech's stock. Their predictions range from C$3.25 to C$14.00. On average, they expect Oncolytics Biotech's stock price to reach C$8.63 in the next year. This suggests a possible upside of 109.9% from the stock's current price. View Analyst Price Targets for Oncolytics Biotech. What is the consensus analysts' recommendation for Oncolytics Biotech? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oncolytics Biotech. Who are some of Oncolytics Biotech's key competitors? Some companies that are related to Oncolytics Biotech include MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Protalix Biotherapeutics (PLX), Neptune Wellness Solutions (NEPT), Monash IVF Group (MVF), ABcann Global (ABCN), Horizon Discovery Group (HZD), IMV (IMV), Faron Pharmaceuticals Oy (FARN), Bionomics (BNO), Fennec Pharmaceuticals (FRX) and ImmunoVaccine (IMMVF). Who are Oncolytics Biotech's key executives? Oncolytics Biotech's management team includes the folowing people: Dr. Matthew C. Coffey, Pres, CEO & DirectorMr. Kirk J. Look, Chief Financial OfficerMr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 51)Mr. Michael Moore, VP of Investor Relations & Corp. CommunicationsDr. Daniel Douglas Von Hoff M.D., F.A.C.P., Consultant (Age 70) How do I buy shares of Oncolytics Biotech? Shares of ONC and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab. What is Oncolytics Biotech's stock price today? One share of ONC stock can currently be purchased for approximately C$4.11. How big of a company is Oncolytics Biotech? Oncolytics Biotech has a market capitalization of C$111.15 million. What is Oncolytics Biotech's official website? The official website for Oncolytics Biotech is http://www.oncolyticsbiotech.com. How can I contact Oncolytics Biotech? Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The company can be reached via phone at +1-403-6707380. MarketBeat Community Rating for Oncolytics Biotech (TSE ONC)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 128 (Vote Outperform)Underperform Votes: 100 (Vote Underperform)Total Votes: 228MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe ONC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/16/2018 by MarketBeat.com StaffFeatured Article: Do closed-end mutual funds pay dividends?